Ocana, Alberto https://orcid.org/0000-0002-1067-9630
Gil-Martin, Marta
Antolín, Silvia
Atienza, María
Montaño, Álvaro
Ribelles, Nuria
Urruticoechea, Ander
Falcón, Alejandro
Pernas, Sonia
Orlando, Javier
Montero, Juan Carlos
Escudero, Maria José
Benito, Sara
Caballero, Rosalía
Carrasco, Eva
Rojo, Federico
Pandiella, Atanasio
Ruiz-Borrego, Manuel
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Received: 7 December 2018
Accepted: 12 December 2018
First Online: 3 January 2019
Compliance with ethical standards
:
: Dr. A. Ocaña has received honorarium for consultant/advisory from Daiichi Sankyo, Entrechem and Servier. Dr. A. Urruticoechea has received honorarium for consultant/advisory from Roche. Dr. A. Falcón has received honorarium as speaker from Roche and Astra-Zeneca. Dr. S. Pernas has received honorarium as speaker and travel grants from Roche, she also participated as advisor for Polyphor. Dr. E. Carrasco owns Ely Lilly stock options and has received travel grants from Roche. Her husband received honoraria from Celgene, BMS, Janssen Cilag and Takeda. Dr F Rojo has received speaker honorarium from Roche, BMS, Merck and Pfizer. Dr M Ruíz-Borrego received honorarium as speaker and advisory from Roche and Astra-Zeneca. The rest of authors declare that they have no conflict of interest.
: All procedures performed in this study are in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the institutions’ ethical review boards of the participating sites and health authorities in Spain.
: Written informed consent was obtained from all individual participants included in the study.